Cordis will now offer an expanded portfolio of products in select countries to further support the treatment of patients undergoing percutaneous coronary intervention (PCI), from access to intervention and closure. PCI is a nonsurgical procedure that often uses a catheter to place a stent to open blocked coronary arteries caused by coronary artery disease. Coronary artery disease is the most common type of heart disease and is expected to continue to be the leading cause of death globally for the next 20 years.
“We are very excited about this DES agreement with Biosensors, because it represents our strong commitment to expand our product portfolio to support the demands in cardiovascular care today,” said David Wilson, president of Cordis, a Cardinal Health company. “While Cordis is known for developing product innovations, partnerships like this provide an opportunity to rapidly expand our unmatched portfolio and deliver increased value to customers and the patients they serve.”
To continue reading, click here.
